University of Queensland researchers have found that Gherlin, the natural ‘hunger hormone’, could be the key to preventing debilitating chronic constipation experienced by people living with Parkinson’s disease. Associate Professor Sebastian Furness from the UQ School of Biomedical Sciences said the team discovered the body’s receptor for Ghrelin had a… Read More
A new App Note is now available for download entitled ‘Unlock more from your LC/MS‘. See how Cerno MassWorks™ delivers sub-millidalton mass accuracy and >99% spectral accuracy—enabling formula ID on standard LC/MS systems. This detailed application note walks you through the results, method, and impact. Confidently identify unknowns using… Read More
A new App Note is now available for download entitled ‘Unlock more from your LC/MS‘. See how Cerno MassWorks™ delivers sub-millidalton mass accuracy and >99% spectral accuracy—enabling formula ID on standard LC/MS systems. This detailed application note walks you through the results, method, and impact. Confidently identify unknowns using… Read More
This is the latest episode of the free DDW narrated podcast, titled “Innovative uses for biomarkers in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “How biomarkers can help discover new treatments for women’s health” and… Read More
This is the latest episode of the free DDW narrated podcast, titled “Innovative uses for biomarkers in drug discovery”, which covers two articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “How biomarkers can help discover new treatments for women’s health” and… Read More
The START Center for Cancer Research (START) and OneOncology has announced a strategic partnership to launch early phase clinical trial sites. The rollout includes the Los Angeles Cancer Network (LACN, California), The Center for Cancer and Blood Disorders (CCBD, Texas), and Astera Cancer Care (New Jersey). This arrangement builds on… Read More
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Poolbeg Pharma’s POLB 001 as an oral preventative therapy for T-cell engager bispecific antibody-induced Cytokine Release Syndrome (CRS). The FDA grants orphan status to support the development of medicines for rare disorders affecting less than 200,000… Read More
Augustine Therapeutics has dosed the first patient in its Phase I clinical trial evaluating lead candidate AGT-100216, the first peripherally-restricted, selective cytosolic Histone DeACetylase 6 (HDAC6) inhibitor for the treatment of Charcot-Marie-Tooth disease (CMT), an inherited neurological disorder that affects the peripheral nerves responsible for transmitting signals between the brain,… Read More
A new Introductory Guide is now available for download entitled ‘Unlocking the biopharma development pipeline‘. Discover a new generation of molecular sensing technology from Oxford Nanopore Technologies that is transforming the biopharma development pipeline. You’ll explore: How Oxford Nanopore sequencing overcomes challenges faced in the drug development process Advantages… Read More
A new Introductory Guide is now available for download entitled ‘Unlocking the biopharma development pipeline‘. Discover a new generation of molecular sensing technology from Oxford Nanopore Technologies that is transforming the biopharma development pipeline. You’ll explore: How Oxford Nanopore sequencing overcomes challenges faced in the drug development process Advantages… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our news highlights this week focus on drug discovery for metabolic diseases, with a… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our news highlights this week focus on drug discovery for metabolic diseases, with a… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Phil L’Huillier, CEO of… Read More
In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Phil L’Huillier, CEO of… Read More
Herantis Pharma has dosed the first patients in the final cohort of its Phase Ib clinical trial evaluating the safety and tolerability of HER-096 in patients with Parkinson’s disease. Commenting on the study, Antti Vuolanto, CEO of Herantis Pharma, said: “Parkinson’s disease is a life altering condition, and there is… Read More
MetaVia has announced that data from its Phase IIa clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH), demonstrates both hepatoprotective and glucose-regulating effects. The data was presented in a late-breaking poster presentation at the European Association for the Study… Read More
